Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report
Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be consid...
Saved in:
| Published in | Allergy, asthma, and clinical immunology Vol. 17; no. 1; pp. 40 - 14 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
19.04.2021
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1710-1492 1710-1484 1710-1492 |
| DOI | 10.1186/s13223-021-00537-2 |
Cover
| Abstract | Background
Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient’s frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE.
Methods
A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting.
Results
Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient’s QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden.
Conclusion
This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. |
|---|---|
| AbstractList | Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient's frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. Methods A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Results Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient's QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. Conclusion This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. Keywords: Consensus document, Disease burden, Hereditary angioedema, Management, Quality of life Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient’s frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. Methods A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Results Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient’s QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. Conclusion This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient's frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient's QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient's frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE.BACKGROUNDHereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient's frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE.A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting.METHODSA consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting.Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient's QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden.RESULTSFinal statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient's QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden.This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE.CONCLUSIONThis consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. Abstract Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient’s frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. Methods A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Results Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient’s QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. Conclusion This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient’s frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. Methods A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Results Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient’s QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. Conclusion This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and emotional burdens for patients and families. To optimize care for patients with HAE, an individualized management plan should be considered in partnership with the physician, requiring comprehensive assessment of the patient's frequency and severity of attacks, disease burden, and therapeutic control. Although several guidelines and consensus papers have been published concerning the diagnosis and treatment of HAE, there has been limited specific clinical guidance on the assessment of disease burden and quality of life (QoL) in this patient population. Practical guidance is critical in supporting effective long-term clinical management of HAE and improving patient outcomes. The objective of this review is to provide evidence-based guidelines for an individualized assessment of disease burden and QoL in patients with HAE. A consensus meeting was held on February 29, 2020, consisting of 9 HAE experts from the United States and Europe with extensive clinical experience in the treatment of HAE. Consensus statements were developed based on a preliminary literature review and discussions from the consensus meeting. Final statements reflect the consensus of the expert panel and include the assessment of attack severity, evaluation of disease burden, and long-term clinical management of HAE caused by C1-esterase inhibitor deficiency. Patient-reported outcome measures for assessing HAE attack severity and frequency are available and valuable tools; however, attack frequency and severity are insufficient markers of disease severity unless they are evaluated in the broader context of the effect on an individual patient's QoL. QoL assessments should be individualized for each patient and minimally, they should address the interference of HAE with work, school, social, family, and physical activity, along with access to and burden of HAE treatment. Advances in HAE therapies offer the opportunity for comprehensive, individualized treatment plans, allowing patients to achieve minimal attack burden with reduced disease and treatment burden. This consensus report builds on existing guidelines by expanding the assessment of disease burden and QoL measures for patients with HAE. |
| ArticleNumber | 40 |
| Audience | Academic |
| Author | Longhurst, Hilary J. Anderson, John T. Li, H. Henry Radojicic, Cristine Caballero, Teresa Craig, Timothy Johnston, Douglas T. Riedl, Marc A. Bork, Konrad |
| Author_xml | – sequence: 1 givenname: Konrad surname: Bork fullname: Bork, Konrad email: konrad.bork@unimedizin-mainz.de organization: Department of Dermatology, University Medical Center, Johannes Gutenberg University – sequence: 2 givenname: John T. surname: Anderson fullname: Anderson, John T. organization: Clinical Research Center of Alabama – sequence: 3 givenname: Teresa surname: Caballero fullname: Caballero, Teresa organization: Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754) – sequence: 4 givenname: Timothy surname: Craig fullname: Craig, Timothy organization: Department of Medicine and Pediatrics, Penn State University – sequence: 5 givenname: Douglas T. surname: Johnston fullname: Johnston, Douglas T. organization: Asthma and Allergy Specialists – sequence: 6 givenname: H. Henry surname: Li fullname: Li, H. Henry organization: Institute for Asthma and Allergy – sequence: 7 givenname: Hilary J. surname: Longhurst fullname: Longhurst, Hilary J. organization: Addenbrookes Hospital, Cambridge Universities NHS Foundation Trust, Cambridge and University College Hospital London – sequence: 8 givenname: Cristine surname: Radojicic fullname: Radojicic, Cristine organization: Division of Allergy and Clinical Immunology, Department of Medicine, Duke University – sequence: 9 givenname: Marc A. surname: Riedl fullname: Riedl, Marc A. organization: University of California San Diego |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33875020$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhSNURB_wB1igSEiITYof8SMskEYVj0qV2MDacuKbjKvEntoOqPx6nJmWzlSoyiKxfc4X33vPaXHkvIOieI3ROcaSf4iYEkIrRHCFEKOiIs-KEywwqnDdkKO97-PiNMZrhGosKXlRHFMqBUMEnRR_VjFCjBO4VGpnykk7PcB26fvS2Ag6QtnOwYDbCm5mPdp0u5yOtofSunKjk82GWP62aV2uIYCxSYfbrB-sBwOT_ljqsvMugotzLANsfEgvi-e9HiO8unufFT-_fP5x8a26-v718mJ1VXWcylS1reCY9B0hRktOMfS1Ica00mDZASUISaMZabhomgZxXXPdgtGcIGEYo4SeFZc7rvH6Wm2CnfLdlNdWbTd8GJQOyXYjKMmIoKKTrWCkbrnIMCRaSWXLuZSszqxPO9ZmbicwXS476PEAenji7FoN_peSiPHsz4D3d4Dgb2aISU02djCO2oGfoyIMMy5pQ5osfftIeu3n4HKrFlUtJJKYPKgGnQuwrvf5v90CVSvOcY1rxBfW-X9U-cnDsXkw0Nu8f2B4t2dYgx7TOvpxTjZP8VD4Zr8j_1pxH7EskDtBF3yMAXrV5XQsnHwFOyqM1JJmtUuzymlW2zSrpTbyyHpPf9JEd6aYxW6A8NC2J1x_AR5JBLg |
| CitedBy_id | crossref_primary_10_1016_j_anai_2023_10_011 crossref_primary_10_1111_all_15214 crossref_primary_10_1016_j_jaip_2023_12_019 crossref_primary_10_2500_aap_2021_42_210066 crossref_primary_10_1007_s12016_024_09006_1 crossref_primary_10_1097_MOH_0000000000000727 crossref_primary_10_1016_j_waojou_2024_100882 crossref_primary_10_2478_amma_2024_0009 crossref_primary_10_2500_aap_2024_45_230073 crossref_primary_10_1016_j_anai_2025_01_007 crossref_primary_10_7759_cureus_51959 crossref_primary_10_1182_blood_2023022254 crossref_primary_10_1186_s13223_025_00953_8 crossref_primary_10_2500_aap_2024_45_230080 crossref_primary_10_1016_j_jaip_2024_12_008 crossref_primary_10_1056_NEJMoa2314192 crossref_primary_10_1016_j_jaip_2023_12_025 crossref_primary_10_1016_j_waojou_2023_100792 crossref_primary_10_1111_joim_20008 crossref_primary_10_1016_j_waojou_2023_100758 crossref_primary_10_1186_s41687_023_00576_w crossref_primary_10_1097_ACI_0000000000001042 crossref_primary_10_26442_00403660_2021_12_201294 crossref_primary_10_1016_j_waojou_2022_100627 crossref_primary_10_3390_metabo12111140 crossref_primary_10_3389_fimmu_2025_1550380 crossref_primary_10_3389_falgy_2023_1143897 crossref_primary_10_1080_14712598_2024_2441845 crossref_primary_10_1371_journal_pdig_0000090 crossref_primary_10_5415_apallergy_0000000000000172 crossref_primary_10_1111_cea_14568 crossref_primary_10_1186_s13023_024_03247_1 crossref_primary_10_1016_j_waojou_2023_100784 crossref_primary_10_1007_s40629_022_00223_8 crossref_primary_10_1016_S0140_6736_23_00350_1 crossref_primary_10_1002_clt2_12092 crossref_primary_10_3389_fmed_2024_1343547 crossref_primary_10_1182_blood_2021012945 crossref_primary_10_26416_Aler_8_2_2024_9779 crossref_primary_10_33590_emjallergyimmunol_10166350 crossref_primary_10_3389_fped_2023_1141073 crossref_primary_10_1016_j_waojou_2024_100918 crossref_primary_10_1186_s13023_022_02360_3 crossref_primary_10_1016_j_drudis_2024_103890 crossref_primary_10_1186_s40537_023_00767_8 crossref_primary_10_3390_ijms231810332 crossref_primary_10_1007_s15007_022_5601_y crossref_primary_10_1016_S2352_3026_24_00081_4 crossref_primary_10_1016_j_anai_2023_03_028 |
| Cites_doi | 10.1001/jama.2018.16773 10.1016/j.anai.2017.05.017 10.1016/j.amjmed.2005.09.064 10.1056/NEJMoa1613627 10.18176/jiaci.0479 10.2500/aap.2017.38.4087 10.1186/s13023-016-0518-8 10.1007/s12016-016-8561-8 10.1016/j.jaci.2017.05.020 10.1111/j.1398-9995.2011.02751.x 10.2340/00015555-1835 10.1007/s12016-014-8463-6 10.1016/j.iac.2017.04.005 10.1056/NEJM197208312870907 10.1159/000441060 10.1007/s10875-012-9734-8 10.2500/aap.2012.33.3597 10.1186/s13223-019-0376-8 10.1016/j.anai.2013.07.012 10.2500/aap.2019.40.4200 10.1056/NEJMoa0905079 10.1111/all.12209 10.1016/j.anai.2013.05.028 10.1111/cei.12379 10.1016/j.amjmed.2011.12.016 10.2500/aap.2013.34.3685 10.1016/j.anai.2015.06.006 10.1016/j.jaci.2013.03.034 10.2500/aap.2015.36.3824 10.1016/j.jaip.2015.12.010 10.1016/j.jaip.2014.09.001 10.1016/j.jaip.2017.12.039 10.1016/j.jaip.2013.07.002 10.1016/j.tripleo.2011.02.034 10.1111/all.14454 10.1007/s11136-009-9509-8 10.1186/s13023-019-1159-5 10.1016/j.jaci.2020.10.015 10.2500/aap.2014.35.3783 10.1111/pai.13060 10.1056/NEJMoa0805538 10.1016/j.jaci.2017.12.154 10.1056/NEJM197612232952602 10.1111/j.1572-0241.2006.00492.x 10.2500/aap.2012.33.3627 10.2340/00015555-1743 10.1186/1750-1172-9-99 10.1016/j.anai.2013.08.019 10.1111/all.14144 10.1056/NEJMoa0906393 10.1111/all.12007 10.2165/11597490-000000000-00000 10.2500/aap.2010.31.3394 10.1186/s13023-018-0797-3 10.2500/aap.2018.39.4123 10.1016/j.jaip.2020.08.046 10.1111/all.13270 10.1111/all.13869 10.2147/PPA.S100383 10.1186/s40413-017-0180-1 10.1016/j.jaip.2018.11.042 10.1016/j.anai.2018.07.025 10.1016/j.jaci.2017.12.165 10.1111/j.1365-2249.2005.02726.x 10.1186/s13223-016-0176-3 10.1016/S1081-1206(10)60424-3 10.1016/j.jaci.2009.03.038 10.1097/ACI.0000000000000163 10.1056/NEJMcp0803977 10.1111/ced.12681 10.6061/clinics/2013(01)OA13 10.1016/j.bbrc.2006.03.092 10.1111/all.12380 10.1016/j.jaci.2012.05.055 10.1016/j.jaip.2020.02.038 10.3389/fmed.2017.00212 10.1016/j.anai.2013.12.004 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88C 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M0T PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13223-021-00537-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Healthcare Administration Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: 开放获取期刊（Open Access Journals） url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1710-1492 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_852737c8b7524b67a4607b838b668854 PMC8056543 A661414069 33875020 10_1186_s13223_021_00537_2 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: BioCryst Pharmaceuticals – fundername: Universitätsmedizin der Johannes Gutenberg-Universität Mainz (8974) – fundername: ; |
| GroupedDBID | --- 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AQUVI BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M0T M48 O5R O5S OK1 P6G PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP AAYXX ALIPV CITATION NPM PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-bb7612fc22da8631ef4d2ddb8d18ce32008da5296799906a46abeda6207d55323 |
| IEDL.DBID | M48 |
| ISSN | 1710-1492 1710-1484 |
| IngestDate | Wed Aug 27 01:21:06 EDT 2025 Thu Aug 21 18:23:38 EDT 2025 Thu Sep 04 19:07:24 EDT 2025 Fri Jul 25 02:52:31 EDT 2025 Tue Jun 17 20:54:53 EDT 2025 Tue Jun 10 20:54:10 EDT 2025 Thu May 22 20:58:06 EDT 2025 Thu Apr 03 06:53:30 EDT 2025 Thu Apr 24 23:11:33 EDT 2025 Tue Jul 01 02:38:42 EDT 2025 Sat Sep 06 07:30:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Consensus document Hereditary angioedema Management Disease burden Quality of life |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-bb7612fc22da8631ef4d2ddb8d18ce32008da5296799906a46abeda6207d55323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13223-021-00537-2 |
| PMID | 33875020 |
| PQID | 2514780812 |
| PQPubID | 2040175 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_852737c8b7524b67a4607b838b668854 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8056543 proquest_miscellaneous_2515683929 proquest_journals_2514780812 gale_infotracmisc_A661414069 gale_infotracacademiconefile_A661414069 gale_healthsolutions_A661414069 pubmed_primary_33875020 crossref_citationtrail_10_1186_s13223_021_00537_2 crossref_primary_10_1186_s13223_021_00537_2 springer_journals_10_1186_s13223_021_00537_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-19 |
| PublicationDateYYYYMMDD | 2021-04-19 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Allergy, asthma, and clinical immunology |
| PublicationTitleAbbrev | Allergy Asthma Clin Immunol |
| PublicationTitleAlternate | Allergy Asthma Clin Immunol |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | 537_CR73 W Lumry (537_CR16) 2010; 31 537_CR72 537_CR75 537_CR74 537_CR77 537_CR76 537_CR79 A Banerji (537_CR15) 2015; 36 S Betschel (537_CR31) 2019; 15 M Cicardi (537_CR90) 2014; 69 V Squeglia (537_CR62) 2016; 11 JA Bernstein (537_CR1) 2018; 24 MA Gomide (537_CR24) 2013; 68 K Bork (537_CR40) 2006; 101 AL Sheffer (537_CR97) 1972; 287 A Kusuma (537_CR41) 2012; 125 K Bork (537_CR10) 2009; 124 537_CR71 537_CR70 V Bafunno (537_CR7) 2018; 141 537_CR68 G Dewald (537_CR6) 2006; 343 537_CR69 B Zuraw (537_CR36) 2020 MA Riedl (537_CR46) 2014; 112 BL Zuraw (537_CR29) 2013; 1 K Weller (537_CR67) 2020; 8 ZL Hofman (537_CR39) 2016; 50 AS Fouche (537_CR20) 2014; 112 537_CR95 537_CR94 M Maurer (537_CR30) 2018; 11 CV McMillan (537_CR47) 2012; 5 BL Zuraw (537_CR35) 2010; 363 BL Zuraw (537_CR3) 2016; 51 WR Lumry (537_CR80) 2015; 168 T Caballero (537_CR54) 2017; 37 WR Lumry (537_CR58) 2018; 141 PJ Busse (537_CR65) 2019; 7 537_CR93 K Weller (537_CR59) 2020; 75 537_CR85 537_CR88 A Aabom (537_CR21) 2015; 95 537_CR87 537_CR89 A Bygum (537_CR37) 2017; 4 BL Zuraw (537_CR84) 2013; 131 MA Riedl (537_CR91) 2017; 119 WR Lumry (537_CR66) 2018; 6 M Cicardi (537_CR4) 2012; 67 SC Christiansen (537_CR64) 2018; 141 K Bork (537_CR81) 2011; 112 NL Jindal (537_CR25) 2017; 13 K Weller (537_CR51) 2013; 68 A Banerji (537_CR13) 2013; 111 MM Gompels (537_CR83) 2005; 139 A Wang (537_CR92) 2015; 115 K Bork (537_CR82) 2008; 100 K Bork (537_CR8) 2018; 73 E Aygören-Pürsün (537_CR18) 2014; 9 K Bork (537_CR12) 2012; 130 A Ariano (537_CR11) 2020; 75 S Nicola (537_CR32) 2019; 8 T Caballero (537_CR19) 2014; 35 JA Gelfand (537_CR96) 1976; 295 K Weller (537_CR60) 2016; 41 L Bouillet (537_CR23) 2013; 111 RG Gower (537_CR14) 2011; 4 JM Forjaz (537_CR52) 2021 W Lumry (537_CR55) 2014; 35 AK Bewtra (537_CR56) 2012; 33 A Banerji (537_CR33) 2018; 320 A Banerji (537_CR43) 2018; 39 K Bork (537_CR9) 2019; 74 K Weller (537_CR53) 2015; 15 PJ Busse (537_CR38) 2021; 9 T Craig (537_CR28) 2018; 121 A Zanichelli (537_CR63) 2018; 13 M Cicardi (537_CR44) 2010; 363 B Zuraw (537_CR2) 2008; 359 K Weller (537_CR57) 2012; 67 T Caballero (537_CR48) 2012; 32 P Nordenfelt (537_CR27) 2017; 38 C Wintenberger (537_CR98) 2014; 178 A Bygum (537_CR17) 2014; 94 YM Arce-Ayala (537_CR22) 2019; 40 E Aygören-Pürsün (537_CR50) 2016; 10 MK Vernon (537_CR49) 2009; 18 B Zuraw (537_CR5) 2012; 33 E Aygören-Pürsün (537_CR86) 2019; 30 K Bork (537_CR42) 2006; 119 S Liu (537_CR26) 2019; 14 M Cicardi (537_CR45) 2010; 363 H Longhurst (537_CR34) 2017; 376 TJ Craig (537_CR78) 2015; 3 N Prior (537_CR61) 2016; 4 |
| References_xml | – volume: 320 start-page: 2108 issue: 20 year: 2018 ident: 537_CR33 publication-title: JAMA doi: 10.1001/jama.2018.16773 – volume: 119 start-page: 59 issue: 1 year: 2017 ident: 537_CR91 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2017.05.017 – volume: 119 start-page: 267 issue: 3 year: 2006 ident: 537_CR42 publication-title: Am J Med doi: 10.1016/j.amjmed.2005.09.064 – ident: 537_CR77 – volume: 376 start-page: 1131 issue: 12 year: 2017 ident: 537_CR34 publication-title: N Engl J Med doi: 10.1056/NEJMoa1613627 – year: 2021 ident: 537_CR52 publication-title: J Investig Allergol Clin Immunol. doi: 10.18176/jiaci.0479 – volume: 38 start-page: 447 issue: 6 year: 2017 ident: 537_CR27 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2017.38.4087 – volume: 11 start-page: 133 issue: 1 year: 2016 ident: 537_CR62 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-016-0518-8 – volume: 51 start-page: 216 issue: 2 year: 2016 ident: 537_CR3 publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-016-8561-8 – volume: 8 start-page: 212605 year: 2019 ident: 537_CR32 publication-title: Drugs Context – volume: 141 start-page: 1009 issue: 3 year: 2018 ident: 537_CR7 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2017.05.020 – volume: 67 start-page: 147 issue: 2 year: 2012 ident: 537_CR4 publication-title: Allergy doi: 10.1111/j.1398-9995.2011.02751.x – volume: 95 start-page: 225 issue: 2 year: 2015 ident: 537_CR21 publication-title: Acta Derm Venereol doi: 10.2340/00015555-1835 – volume: 50 start-page: 34 issue: 1 year: 2016 ident: 537_CR39 publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-014-8463-6 – ident: 537_CR72 – volume: 37 start-page: 597 issue: 3 year: 2017 ident: 537_CR54 publication-title: Immunol Allergy Clin North Am doi: 10.1016/j.iac.2017.04.005 – volume: 287 start-page: 452 issue: 9 year: 1972 ident: 537_CR97 publication-title: N Engl J Med doi: 10.1056/NEJM197208312870907 – volume: 168 start-page: 44 issue: 1 year: 2015 ident: 537_CR80 publication-title: Int Arch Allergy Immunol doi: 10.1159/000441060 – volume: 32 start-page: 1204 issue: 6 year: 2012 ident: 537_CR48 publication-title: J Clin Immunol doi: 10.1007/s10875-012-9734-8 – volume: 33 start-page: 427 issue: 5 year: 2012 ident: 537_CR56 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2012.33.3597 – volume: 15 start-page: 72 year: 2019 ident: 537_CR31 publication-title: Allergy Asthma Clin Immunol doi: 10.1186/s13223-019-0376-8 – ident: 537_CR71 – volume: 111 start-page: 290 issue: 4 year: 2013 ident: 537_CR23 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2013.07.012 – ident: 537_CR79 – ident: 537_CR94 – volume: 40 start-page: 103 issue: 2 year: 2019 ident: 537_CR22 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2019.40.4200 – volume: 363 start-page: 523 issue: 6 year: 2010 ident: 537_CR45 publication-title: N Engl J Med doi: 10.1056/NEJMoa0905079 – volume: 68 start-page: 1185 issue: 9 year: 2013 ident: 537_CR51 publication-title: Allergy doi: 10.1111/all.12209 – volume: 112 start-page: 371 issue: 4 year: 2014 ident: 537_CR20 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2013.05.028 – volume: 178 start-page: 112 issue: 1 year: 2014 ident: 537_CR98 publication-title: Clin Exp Immunol doi: 10.1111/cei.12379 – volume: 125 start-page: 937.e17 issue: 9 year: 2012 ident: 537_CR41 publication-title: Am J Med doi: 10.1016/j.amjmed.2011.12.016 – volume: 35 start-page: 47 issue: 1 year: 2014 ident: 537_CR19 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2013.34.3685 – ident: 537_CR88 – volume: 115 start-page: 120 issue: 2 year: 2015 ident: 537_CR92 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2015.06.006 – volume: 131 start-page: 1491 issue: 6 year: 2013 ident: 537_CR84 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.03.034 – volume: 36 start-page: 213 year: 2015 ident: 537_CR15 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2015.36.3824 – volume: 4 start-page: 464 issue: 3 year: 2016 ident: 537_CR61 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2015.12.010 – volume: 3 start-page: 206 issue: 2 year: 2015 ident: 537_CR78 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2014.09.001 – volume: 6 start-page: 1733 issue: 5 year: 2018 ident: 537_CR66 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2017.12.039 – ident: 537_CR74 – volume: 1 start-page: 458 issue: 5 year: 2013 ident: 537_CR29 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2013.07.002 – volume: 112 start-page: 58 issue: 1 year: 2011 ident: 537_CR81 publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol Endod doi: 10.1016/j.tripleo.2011.02.034 – volume: 75 start-page: 2989 issue: 11 year: 2020 ident: 537_CR11 publication-title: Allergy doi: 10.1111/all.14454 – ident: 537_CR68 – ident: 537_CR85 – volume: 18 start-page: 929 issue: 7 year: 2009 ident: 537_CR49 publication-title: Qual Life Res doi: 10.1007/s11136-009-9509-8 – volume: 14 start-page: 191 issue: 1 year: 2019 ident: 537_CR26 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-019-1159-5 – ident: 537_CR73 – year: 2020 ident: 537_CR36 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2020.10.015 – volume: 35 start-page: 371 issue: 5 year: 2014 ident: 537_CR55 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2014.35.3783 – volume: 30 start-page: 553 issue: 5 year: 2019 ident: 537_CR86 publication-title: Pediatr Allergy Immunol doi: 10.1111/pai.13060 – volume: 363 start-page: 513 issue: 6 year: 2010 ident: 537_CR35 publication-title: N Engl J Med doi: 10.1056/NEJMoa0805538 – volume: 141 start-page: AB47 issue: 2 year: 2018 ident: 537_CR58 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2017.12.154 – volume: 24 start-page: S292 issue: Suppl 14 year: 2018 ident: 537_CR1 publication-title: Am J Manag Care – volume: 295 start-page: 1444 issue: 26 year: 1976 ident: 537_CR96 publication-title: N Engl J Med doi: 10.1056/NEJM197612232952602 – volume: 101 start-page: 619 issue: 3 year: 2006 ident: 537_CR40 publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2006.00492.x – volume: 33 start-page: S145 year: 2012 ident: 537_CR5 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2012.33.3627 – volume: 94 start-page: 436 issue: 4 year: 2014 ident: 537_CR17 publication-title: Acta Derm Venereol doi: 10.2340/00015555-1743 – volume: 9 start-page: 99 year: 2014 ident: 537_CR18 publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-9-99 – ident: 537_CR93 – volume: 111 start-page: 329 issue: 5 year: 2013 ident: 537_CR13 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2013.08.019 – volume: 75 start-page: 1165 issue: 5 year: 2020 ident: 537_CR59 publication-title: Allergy doi: 10.1111/all.14144 – ident: 537_CR76 – volume: 363 start-page: 532 issue: 6 year: 2010 ident: 537_CR44 publication-title: N Engl J Med doi: 10.1056/NEJMoa0906393 – volume: 67 start-page: 1289 issue: 10 year: 2012 ident: 537_CR57 publication-title: Allergy doi: 10.1111/all.12007 – volume: 5 start-page: 113 issue: 2 year: 2012 ident: 537_CR47 publication-title: Patient doi: 10.2165/11597490-000000000-00000 – volume: 31 start-page: 407 issue: 5 year: 2010 ident: 537_CR16 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2010.31.3394 – volume: 13 start-page: 51 issue: 1 year: 2018 ident: 537_CR63 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-018-0797-3 – volume: 39 start-page: 212 issue: 3 year: 2018 ident: 537_CR43 publication-title: Allergy Asthma Proc doi: 10.2500/aap.2018.39.4123 – ident: 537_CR87 – volume: 9 start-page: 132 issue: 1 year: 2021 ident: 537_CR38 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.08.046 – volume: 73 start-page: 442 issue: 2 year: 2018 ident: 537_CR8 publication-title: Allergy doi: 10.1111/all.13270 – volume: 74 start-page: 2479 issue: 12 year: 2019 ident: 537_CR9 publication-title: Allergy doi: 10.1111/all.13869 – volume: 10 start-page: 1699 year: 2016 ident: 537_CR50 publication-title: Patient Prefer Adherence doi: 10.2147/PPA.S100383 – ident: 537_CR75 – volume: 11 start-page: 5 year: 2018 ident: 537_CR30 publication-title: World Allergy Organ J doi: 10.1186/s40413-017-0180-1 – volume: 7 start-page: 1679 issue: 5 year: 2019 ident: 537_CR65 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2018.11.042 – volume: 121 start-page: 673 issue: 6 year: 2018 ident: 537_CR28 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2018.07.025 – volume: 141 start-page: AB51 issue: 2 year: 2018 ident: 537_CR64 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2017.12.165 – volume: 139 start-page: 379 issue: 3 year: 2005 ident: 537_CR83 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2005.02726.x – volume: 13 start-page: 4 year: 2017 ident: 537_CR25 publication-title: Allergy Asthma Clin Immunol doi: 10.1186/s13223-016-0176-3 – ident: 537_CR69 – volume: 100 start-page: 153 issue: 2 year: 2008 ident: 537_CR82 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)60424-3 – volume: 124 start-page: 129 issue: 1 year: 2009 ident: 537_CR10 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2009.03.038 – volume: 15 start-page: 220 issue: 3 year: 2015 ident: 537_CR53 publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0000000000000163 – volume: 359 start-page: 1027 issue: 10 year: 2008 ident: 537_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMcp0803977 – ident: 537_CR70 – volume: 41 start-page: 91 issue: 1 year: 2016 ident: 537_CR60 publication-title: Clin Exp Dermatol doi: 10.1111/ced.12681 – ident: 537_CR95 – volume: 68 start-page: 81 issue: 1 year: 2013 ident: 537_CR24 publication-title: Clinics (Sao Paulo) doi: 10.6061/clinics/2013(01)OA13 – ident: 537_CR89 – volume: 343 start-page: 1286 issue: 4 year: 2006 ident: 537_CR6 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.03.092 – volume: 69 start-page: 602 issue: 5 year: 2014 ident: 537_CR90 publication-title: Allergy doi: 10.1111/all.12380 – volume: 130 start-page: 692 issue: 3 year: 2012 ident: 537_CR12 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2012.05.055 – volume: 8 start-page: 2050 issue: 6 year: 2020 ident: 537_CR67 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.02.038 – volume: 4 start-page: 212 year: 2017 ident: 537_CR37 publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2017.00212 – volume: 4 start-page: 9 issue: Suppl 2 year: 2011 ident: 537_CR14 publication-title: WAO J – volume: 112 start-page: 163 issue: 2 year: 2014 ident: 537_CR46 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2013.12.004 |
| SSID | ssj0041832 |
| Score | 2.4616933 |
| SecondaryResourceType | review_article |
| Snippet | Background
Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant... Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant physical and... Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in significant... Abstract Background Hereditary angioedema (HAE) is a rare disease characterized by unpredictable, potentially life-threatening attacks, resulting in... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 40 |
| SubjectTerms | Abdomen Activities of daily living Allergology Angioedema Angioneurotic edema Care and treatment Consensus document Disease burden Disease prevention Edema Exercise Family Health aspects Hereditary angioedema Immunology Management Medical research Medicine Medicine & Public Health Medicine, Experimental Mutation Patients Pneumology/Respiratory System Quality of life Rare diseases Review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QDogL4pvCgCAhcYBqLx9NMm4PxDQhjROTdovyVfakrW9a3zuMvx47acs6BFy4No6UOLZj1_YvhLzhOsikhah9A-6bTBF0zgldyxC1xzKFFPA_5NFXdXgsv5w0J9ee-sKasAIPXBi3ZxAhTAfjdcOlV9pJtdDeCOOVMqbJSKBwjY3BVLHBEgV1bJExaq_HmAvzlRA6I4BJzWfXUEbr_90mX7uUbhZM3sia5svo4B65O3iRdFlWf5_cSt0DcvtoyJM_JD-WE-AmdV2k51ORC123dEjKUJ9bGDJB6a28wtGzVZvoqqMD4mpP8VctPcU3PVcbd3kF9N9X6xTTuftAHQ1Yjt31256W9MMjcnzw-dunw3p4ZaEOoHub2nsNXk4bOI_OKMFSKyOP0ZvITEgC6yOiw-ysBl9yoYD_zqfoFF_o2DSCi8dkp1t36SmhjOkg9qNzKsDlyBTGKjhd8KZtmWYVYSPTbRggyPEljDObQxGjbDkoCwdl80FZXpF305yLAsDxV-qPeJYTJYJn5w8gUnYQKfsvkarIK5QEWzpRJxNgl-jLMGwVrsjbTIFGADYQ3NDLAGxAOK0Z5e6MEpQ3zIdHabOD8egtuJxS44sosJ3X0zDOxIK4Lq23maZR2bmtyJMinNOmhYAgFMKAiuiZ2M64Mh_pVqcZWtyAP9xIUZH3o4D_Wtafuf7sf3D9ObnDs4LKmu3vkp3N5Ta9AIdv419m3f4JVBRNBw priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1NaxQxNGgF8SJ-O1o1guBBh-4kmST1IqtYilBPFvYW8jXtQjtTd3YP9df7XiY7dSr2OnmBSd533hch75jyIirOS1eD-SZiAJ6zXJXCB-UwTSF6fIc8-iEPj8X3Rb3ID259TqvcysQkqEPn8Y18D_SwUDgmgn2--FXi1CiMruYRGrfJnQpMFaRqtRgdLoHkmgoiMQNBaLEtmtFyr0cvDCOY4ExjS5OSTRRT6t__r5T-S01dT6G8FkdN6ungAbmf7Uo6HwjhIbkV20fk7lGOnD8mv-djC05q20DPx7QX2jU0h2moS0UNCWCotrzE1bNlE-mypbkHa0_x8Zae4pTP5dquLgH-ZNnFEM_tJ2qpxwTttt_0dAhIPCHHB99-fj0s89yF0gM3rkvnFNg9jWcsWC15FRsRWAhOh0r7yDFjIliM1yqwLmfSCmldDFaymQp1zRl_Snbaro3PCa0q5fl-sFZ6UJeVRO8Ft3NWNw3gpSDV9tKNz03JcTbGmUnOiZZmQJQBRJmEKMMK8mHcczG05LgR-gvicoTEdtrpQ7c6MZk7jcY2dMprp2omnFRwpJlymmsnpda1KMgbpAQz1KaOQsHM0bqpsHi4IO8TBIoFOIC3uboBrgEbbE0gdyeQwM5-urylNpPFSW-uiL8gb8dl3Ikpcm3sNgmmlsncLcizgTjHQ3MObik4BgVRE7Kd3Mp0pV2epmbjGizkWvCCfNwS-NVv_f_WX9x8ipfkHkusJ8pqf5fsrFeb-AqMu7V7nTj4D3CkSEo priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LaxRBEG4kgngR346J2oLgQQe3p5_xti6GIMSTgdyafo0ZSGYls3uIvz5VPQ8z8QFet6thu-vRX09VfU3Im0oHkTTnpZcA30SK4HOO61KEqD2WKaSA3yGPvqrDY_HlRJ4MNDnYC3M9f8-M-tDhbQkzjXDpReqREsLtbQmBF8v3Vmo1Rl2Bpjk2xfxx3uzgyfz8v0fha8fQzRLJG3nSfPwc3Cf3BtxIl72iH5BbqX1I7hwNmfFH5Odyotikro30fCproeuaDmkY6nPTQhbouykvcfSsqRNtWjpwrHYUP87SU3zFs9m4i0uQ_96sU0zn7iN1NGABdtttO9onHB6T44PP31aH5fCuQhnA2zal9xpwTR2qKjqjOEu1iFWM3kRmQuJYEREd5mM1oMeFckI5n6JT1UJHKXnFn5Cddt2mZ4QypgPfj86pAMchU3g7wem8knXNNCsIGzfdhoF0HN--OLP58mGU7RVlQVE2K8pWBXk3zfnRU278U_oT6nKSRLrs_ANYkR28zxqkmdPBeC0r4ZWGJS20N9x4pYyRoiCv0BJs33s6Ob1dInph2BxckLdZAt0eFhDc0L0A24AEWjPJvZkkuGuYD4_WZodw0VkAmULjGyiwnNfTMM7EErg2rbdZRqoMZwvytDfOadGcw7UTgH9B9MxsZ7syH2mb00wmbgABS8EL8n408F9_6--7_vz_xHfJ3Sq7oijZ_h7Z2Vxs0wsAcxv_MnvxFR6XPzQ priority: 102 providerName: Springer Nature |
| Title | Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report |
| URI | https://link.springer.com/article/10.1186/s13223-021-00537-2 https://www.ncbi.nlm.nih.gov/pubmed/33875020 https://www.proquest.com/docview/2514780812 https://www.proquest.com/docview/2515683929 https://pubmed.ncbi.nlm.nih.gov/PMC8056543 https://doaj.org/article/852737c8b7524b67a4607b838b668854 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: RBZ dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: KQ8 dateStart: 20090101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: KQ8 dateStart: 20050101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: 开放获取期刊（Open Access Journals） customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: DOA dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: ABDBF dateStart: 20080301 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals - Free Access to All customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: DIK dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: GX1 dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: RPM dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1710-1492 dateEnd: 20250228 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: M48 dateStart: 20050301 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: AAJSJ dateStart: 20050301 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) customDbUrl: eissn: 1710-1492 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0041832 issn: 1710-1492 databaseCode: C6C dateStart: 20050301 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1paxQxNPQA8Yt4O1rXCKIfdOpOkklSQWS7tBRhi4gL-y3kmnZhO9vuAa6_3rzMoVOr-HEnL8vkHfPey7sQekWEZV5Qmpo8mG_MuyBzmoqUWScMpCl4C_eQo1N-MmafJ_lkCzXptjUClze6djBParyY7X-_2nwKAv8xCrzk75fgUUE0MjjG0J4kJa8vr1IYLAUB2HrKxjbaDcqKAOOPWBtoYMDRsWYSkhSYZE1dzY1_29FdscX_nx_y3zTZ9SzLa6HWqMGO76I7temJBxWv3ENbvryPbo3q4PoD9GPQdunEunT4os2MwfMC15EcbGLdQwSoCjI3sDqbFh5PS1y3aV1iuN_F5zAIdLrSi02AP5vOvfMX-gPW2EIOd7lcL3EVs3iIxsdH34YnaT2aIbVBYFepMSKYRoUlxGnJaeYL5ohzRrpMWk8hqcJpCOmKYID2uWZcG-80J33h8pwS-gjtlPPSP0E4y4SlB05rboNGzTg4OLCdkrwoAl0SlDVIV7buWw7jM2Yq-i-Sq4pQKhBKRUIpkqC37Z7LqmvHP6EPgZYtJHTcjg_mizNVC7CS0KlOWGlETpjhIhypL4yk0nAuZc4S9AI4QVXlq-13Qw3AAMqgvjhBbyIE8HI4gNV1AURAA_Tg6kDudSCDxNvucsNtqhEYFexUJmCMSjjOy3YZdkIWXenn6wiT82gRJ-hxxZztoSkNnmvwHRIkOmzbwUp3pZyex37kMhjROaMJetcw-K_X-jvWn_7Haz5Dt0mUP5ZmB3toZ7VY--fBCFyZHtoWE9FDu4dHp1--hl9DPuzFC5VeFPCftRRZXw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELaqIgEviJtAoUYC8QBRN7Zju0gILUe1pd0-tdK-GV9pV2qTsofQ8qP4jXico6SIvvV1PZbWnvEcmZlvEHpFhGVeUJqaPLhvzLvw5jQVKbNOGChT8Ba-Q44P-OiIfZvkkzX0u-2FgbLKVidGRe0qC9_It4IdZgLGRJCP5z9SmBoF2dV2hEYtFnt-9TOEbPMPu18Cf18TsvP18PMobaYKpDbI2iI1JkTupLCEOC05zXzBHHHOSJdJ6ynUAzgN2UgRfKcB14xr453mZCBcnlMAOggq_wajAwZY_WLSBXgMnkdswISKByZZ26Qj-dYcoj7ImIbgHSBUUtIzhHFewL9W4S-zeLlk81LeNprDnbvoTuPH4mEtePfQmi_vo5vjJlP_AP0adpCfWJcOn3VlNrgqcJMWwiY2UUSCurtzBaun08LjaYkbzNc5ho_F-ASmik4XerYK9MfTyjt_pt9jjS0UhJfz5RzXCZCH6OhaOPIIrZdV6Z8gnGXC0m2nNbfBPGccoiXYTkleFIEvCcraS1e2AUGHWRynKgZDkquaUSowSkVGKZKgt92e8xoC5ErqT8DLjhLgu-MP1exYNdpASYC9E1YakRNmuAhHGggjqTScS5mzBG2CJKi6F7ZTQmoI3lQGzcoJehMpQA2FA1jddFOEawBArx7lRo8yqA_bX26lTTXqa64uHluCXnbLsBNK8kpfLSNNzqN7naDHtXB2h6Y0hMEhEEmQ6Ilt71b6K-X0JIKby-CR54wm6F0r4Bd_6_-3_vTqU2yiW6PD8b7a3z3Ye4Zuk_gMWZptb6D1xWzpnwfHcmFexNeM0ffrVh9_AL7_hOg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELZQK1W8IMqZUqiRkHiAqJvYsb28LceqLLRCgkp9s3yljdRmqz0e2l_PjHPQlEPidT2W1vbM-JvMzGdCXuXS8SAZS20B8I0HDzZnmEy589JimUJw-B3y8EgcHPPZSXFyo4s_Vrt3KcmmpwFZmurV_qUvGxNXYn-JMRTmHyEURkKSFJzwpirGAsKvzclk9n3WeWOOKts1y_xx5uBCirz9v3vnG9fT7dLJW_nTeC1N75N7LZ6kk0YBtsmdUD8gW4dtxvwhuZ701JvU1J5e9OUudF7SNj1DbWxmiAJNl-UVjp5XZaBVTVvu1SXFj7b0DF_3rFZmcQXyp9U8-HBh3lFDHRZm18v1kjaJiEfkePrpx4eDtH1vIXVghavUWgl4p3R57o0SLAsl97n3VvlMucCwUsIbzNNKQJUjYbgwNngj8pH0RcFy9phs1PM6PCU0y6RjY2-McHBNZgKjFpzO8qIsM5klJOs2XbuWjBzfxDjXMShRQjcHpeGgdDwonSfkTT_nsqHi-Kf0ezzLXhJptOMP88Wpbq1SK6Sfk05ZWeTcCglLGkmrmLJCKFXwhOyhJuimJ7V3BnqCqCbDpuGEvI4S6A5gAc60XQ2wDUisNZDcHUiCGbvhcKdtunUjSw3gk0t8GwWW87IfxplYGleH-TrKFCLC3IQ8aZSzXzRjEI5CQJAQOVDbwa4MR-rqLJKMK0DGBWcJedsp-K-_9fdd3_k_8T2y9e3jVH_9fPTlGbmbR6vkaTbeJRurxTo8B7y3si9ak_4JNGZL3w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+and+management+of+disease+burden+and+quality+of+life+in+patients+with+hereditary+angioedema%3A+a+consensus+report&rft.jtitle=Allergy%2C+asthma%2C+and+clinical+immunology&rft.au=Bork%2C+Konrad&rft.au=Anderson%2C+John+T&rft.au=Caballero%2C+Teresa&rft.au=Craig%2C+Timothy&rft.date=2021-04-19&rft.issn=1710-1484&rft.volume=17&rft.issue=1&rft.spage=40&rft_id=info:doi/10.1186%2Fs13223-021-00537-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1710-1492&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1710-1492&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1710-1492&client=summon |